PTCT Q4 2024 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$213M-30.6% YoY

Gross Profit

$197M92.4% margin

Operating Income

-$162M-76.2% margin

Net Income

-$66M-30.9% margin

EPS (Diluted)

$-0.85

QoQ Revenue Growth

+8.3%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$37M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$2.8B

Stockholders' Equity

-$1.1B

Cash & Equivalents

$780M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$213M	$307M	-30.6%
Gross Profit	$197M	$201M	-1.9%
Operating Income	-$162M	$3M	-5304.8%
Net Income	-$66M	-$156M	+57.7%

Revenue Segments

Product

$466M77%

Royalty

$142M23%